New drug shows promise in wiping out hidden myeloma cells after transplant
NCT ID NCT03477539
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to control the disease, patients may still need ongoing management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug's real-world performance match clinical trial results?
- Can a maintenance drug keep myeloma at bay?
- New hope for frail myeloma patients: phase III trial tests smarter drug combos
- Could a tiny dose of radiation ease myeloma bone pain?
- Could a common allergy pill ease bone pain in myeloma treatment?
- New vaccine aims to train immune system against myeloma